Immuron Overview

  • Status
  • Public
  • Employees
  • 6
Employees
  • Stock Symbol
  • IMC
Stock Symbol
  • Share Price
  • $0.26
  • (As of Friday Closing)

Immuron General Information

Description

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Contact Information

Formerly Known As
Anadis
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
ASX
Primary Office
  • Building 10
  • 25-37 Chapman Street
  • Blackburn North, Victoria 3131
  • Australia
+61 (03) 0000 0000

Immuron Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immuron Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.26 $0.28 $0.03 - $0.67 $57.3M 221M 3.58M -$0.02

Immuron Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019 FY 2018 30-Jun-2018
EV 28,341 28,341 10,765 35,444
Revenue 1,688 1,688 1,707 1,428
EBITDA (1,948) (1,948) (3,309) (2,311)
Net Income (1,962) (1,962) (3,312) (2,332)
Total Assets 4,262 4,262 5,996 6,790
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immuron Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immuron‘s full profile, request access.

Request a free trial

Immuron Executive Team (6)

Name Title Board Seat Contact Info
Gary Jacob Ph.D Chief Executive Officer & Board Member
Phillip Hains Chief Financial Officer, Finance & Secretary, Administration
Jerry Kanellos Ph.D Chief Operating Officer, Operations
Peter Anastastiou Executive Vice Chairman
You’re viewing 4 of 6 executive team members. Get the full list »

Immuron Board Members (4)

Name Representing Role Since
0000 00000 00.0 Immuron Chief Executive Officer & Board Member 000 0000
00000 00000000000 Immuron Executive Vice Chairman 000 0000
0000 00000000000 Immuron Board Member 000 0000
To view Immuron’s complete board members history, request access »

Immuron Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial